Randomly controlled drivers using minimally invasive sampling: assessment of drug prevalence in Western Switzerland over two time periods
Joye et al.
The finding, in our words
Roadside controls using minimally invasive sampling, oral fluid (2006-2008) and dried blood spots (2017-2020), found 10.5% of volunteer drivers tested positive for substances affecting driving ability. Illicit drug positivity was highest in under-35s during nights and weekends, and drivers perceived their risk of detection as low (3.3/10). Shows value of systematic biofluid sampling for public health surveillance.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
Dried matrix spot techniques enable minimally invasive opioid monitoring across blood, urine, and saliva with enhanced sample stability and simpler transport, yet suffer from low volumes, matrix-specific recovery issues, and lack of standardisation. Optimising paper substrates and integrating with automated miniaturised mass spectrometry would improve their reliability for decentralised and point-of-care applications.
This narrative review evaluates microsampling devices for therapeutic drug monitoring, concluding that techniques such as volumetric absorptive microsampling and dried blood spots offer reliable, less invasive alternatives to venous sampling when paired with high-sensitivity mass spectrometry, which supports implementation in routine clinical practice.
Dried blood spots detected higher prevalence of anti-inflammatory drug use in ultratrail runners than oral fluid or self-report, indicating DBS is more reliable for drug surveillance at sporting events.
Mashal et al., Drug testing and analysis · source ↗
The analysis indicates that dried blood spots and volumetric absorptive microsampling enable minimally invasive monitoring of prohibited substances, with volumetric absorptive microsampling offering improved quantitative reliability over traditional dried spots.
This review establishes that microsampling across blood, saliva, urine and stool matrices offers validated workflows and regulatory recognition for human biomonitoring comparable to conventional methods. It finds that these decentralised approaches enhance participant acceptability and enable screening in remote or low-resource settings.